Agios Pharmaceuticals (NASDAQ:AGIO) Downgraded by StockNews.com to "Sell"

StockNews.com cut shares of Agios Pharmaceuticals (NASDAQ:AGIO - Free Report) from a hold rating to a sell rating in a research note released on Friday morning.

Other analysts also recently issued reports about the stock. Royal Bank of Canada increased their price target on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an "outperform" rating in a report on Tuesday, December 10th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Agios Pharmaceuticals in a research note on Wednesday, December 18th. Finally, Scotiabank boosted their price target on Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a "sector outperform" rating in a research note on Monday, December 9th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company's stock. According to MarketBeat, Agios Pharmaceuticals presently has an average rating of "Hold" and an average target price of $56.33.

Agios Pharmaceuticals Stock Performance

Shares of Agios Pharmaceuticals stock traded up $0.39 during trading on Friday, reaching $33.61. The company's stock had a trading volume of 869,493 shares, compared to its average volume of 768,458. The business's fifty day moving average price is $34.64 and its 200-day moving average price is $43.21. Agios Pharmaceuticals has a one year low of $26.19 and a one year high of $62.58. The firm has a market cap of $1.92 billion, a price-to-earnings ratio of 2.96 and a beta of 0.88.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last issued its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) EPS for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.93% and a net margin of 2,051.38%. Sell-side analysts anticipate that Agios Pharmaceuticals will post -0.46 EPS for the current year.

Insiders Place Their Bets

In other Agios Pharmaceuticals news, insider Tsveta Milanova sold 2,804 shares of the company's stock in a transaction on Monday, January 6th. The stock was sold at an average price of $32.18, for a total value of $90,232.72. Following the sale, the insider now directly owns 18,906 shares in the company, valued at $608,395.08. This represents a 12.92 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 4.93% of the company's stock.

Institutional Investors Weigh In On Agios Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in AGIO. State Street Corp increased its position in shares of Agios Pharmaceuticals by 10.2% during the 3rd quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company's stock worth $103,586,000 after purchasing an additional 216,484 shares in the last quarter. Vestal Point Capital LP acquired a new stake in shares of Agios Pharmaceuticals during the third quarter worth approximately $33,767,000. BNP Paribas Financial Markets increased its holdings in shares of Agios Pharmaceuticals by 15.1% during the third quarter. BNP Paribas Financial Markets now owns 11,946 shares of the biopharmaceutical company's stock worth $531,000 after buying an additional 1,570 shares in the last quarter. FMR LLC raised its stake in shares of Agios Pharmaceuticals by 283.2% in the third quarter. FMR LLC now owns 45,393 shares of the biopharmaceutical company's stock valued at $2,017,000 after acquiring an additional 33,546 shares during the last quarter. Finally, Intech Investment Management LLC acquired a new position in shares of Agios Pharmaceuticals in the 3rd quarter worth approximately $892,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.